

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Osimertinib for treating EGFR T790M mutation- positive advanced non-small-cell lung cancer [ID1577]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

N/A (no scope issued as CDF review)

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

At the meeting, the patient and clinical experts outlined that there was some regional variation in access to osimertinib during the Cancer Drugs Fund data collection period. Equality of access to treatment is not an equality issue that can be addressed by committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups?

If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, section 3.15

Approved by Associate Director (name): ...Linda Landells.....

Date: 24 August 2020